Small vessel vasculitis can be dangerous, particularly when it affects internal organs like the kidneys and lungs. The severity varies widely depending on the type, whether the disease stays in the skin or spreads to other organ systems, and how quickly treatment begins. Five-year survival rates range from as low as 45% for some forms of microscopic polyangiitis to nearly 100% for milder presentations of eosinophilic granulomatosis, making early diagnosis one of the most important factors in outcomes.
What Makes It Dangerous
Small vessel vasculitis causes inflammation in the walls of tiny blood vessels, including capillaries and small arteries. When that inflammation is limited to the skin, the disease is often manageable. But when it targets blood vessels in the kidneys, lungs, or nervous system, it can cause serious, sometimes life-threatening damage. The vessels become swollen and narrowed, which restricts blood flow and can destroy tissue in the organs they supply.
The most concerning forms are the ANCA-associated vasculitides, a group of conditions where the immune system produces specific antibodies that attack the body’s own white blood cells. These activated white blood cells then damage small blood vessels throughout the body. The three main types in this group are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Each carries a different risk profile, but all can become life-threatening without treatment.
Kidney and Lung Complications
The kidneys are the most frequently affected organ in systemic small vessel vasculitis. Inflamed blood vessels in the kidneys’ filtering units can lead to rapid loss of kidney function, sometimes progressing to the point where dialysis becomes necessary. Among patients with the skin-predominant form called leukocytoclastic vasculitis, renal involvement was the most common extracutaneous complication, found in over 53% of those who developed systemic disease.
Lung involvement is the other major threat. Bleeding into the lungs, known as diffuse alveolar hemorrhage, affects 25 to 60% of people with microscopic polyangiitis and 22 to 30% of those with GPA. This can present as coughing up blood, sudden shortness of breath, or rapidly dropping oxygen levels. It is a medical emergency that requires immediate treatment.
Skin-Limited Disease vs. Systemic Spread
Not all small vessel vasculitis is equally dangerous. When the disease is confined to the skin, it typically appears as small red or purple spots on the lower legs caused by bleeding under the skin. This form, often called cutaneous small vessel vasculitis or leukocytoclastic vasculitis, frequently resolves on its own or with minimal treatment.
The critical question is whether it stays in the skin. In one study of patients initially presenting with leukocytoclastic vasculitis, 58% eventually developed some form of extracutaneous involvement. Kidney problems were most common, followed by joint inflammation (18.5%) and gastrointestinal complications (11.1%). This is why even skin-limited disease needs monitoring. What looks like a minor rash can be the first sign of a broader process.
Five-Year Survival by Type
Survival rates give a clearer picture of relative danger across the different forms:
- Granulomatosis with polyangiitis (GPA): approximately 75% survival at five years
- Microscopic polyangiitis (MPA): 45 to 75% survival at five years, the widest and most concerning range
- Eosinophilic granulomatosis with polyangiitis (EGPA): 68 to 100% survival at five years
- IgA vasculitis (Henoch-Schönlein purpura): approximately 75% survival in adults, higher in children
These numbers reflect the era of modern immunosuppressive treatment. Before effective therapies existed, untreated GPA had a median survival of just five months. Treatment has dramatically changed outcomes, but the numbers make clear that systemic small vessel vasculitis remains a serious condition even with optimal care.
Adults Face Higher Risks Than Children
IgA vasculitis is the most common form of small vessel vasculitis in children and is generally self-limiting in that age group. In adults, the same disease behaves differently. Adults experience a more severe course overall, with higher rates of kidney and gastrointestinal involvement and a greater risk of long-term complications. Adult IgA vasculitis is now considered a distinct clinical entity from the childhood form because of these differences in severity and outcome.
Relapse Is Common
One of the features that makes ANCA-associated vasculitis particularly dangerous is its tendency to come back. Relapse rates in the literature range from 21 to 89% within five years, depending on which medications were used for initial treatment and ongoing maintenance. This means that even after achieving remission, many patients face recurring flares that can cause cumulative organ damage over time. Long-term monitoring and maintenance therapy are standard for this reason.
How Treatment Works
For organ-threatening or life-threatening disease, current guidelines recommend combining high-dose steroids with a powerful immune-suppressing medication. The two primary options for GPA and MPA are rituximab (a targeted therapy that depletes certain immune cells) and cyclophosphamide (a broader immunosuppressant). Rituximab is generally preferred for relapsing disease. For EGPA with serious organ involvement, cyclophosphamide combined with high-dose steroids is the first-line approach.
Steroid doses start high and are tapered down over four to five months, aiming to reach a low maintenance dose relatively quickly. A newer medication called avacopan can be added to reduce the amount of steroids needed, which matters because long-term steroid use carries its own significant side effects.
These treatments work, but they come with real risks. Suppressing the immune system increases vulnerability to infections, including bacterial, viral, and fungal. Rituximab carries a small risk of a rare but serious brain infection called progressive multifocal leukoencephalopathy. It can also reactivate hepatitis B in people who carry the virus. The treatment itself requires careful monitoring, and the balance between controlling the disease and managing medication side effects is something patients navigate for years.
Warning Signs That Need Immediate Attention
Certain symptoms in someone with known or suspected small vessel vasculitis signal a potential emergency. Coughing up blood suggests lung hemorrhage and requires urgent evaluation. A rapid decline in urine output or dark, tea-colored urine points to acute kidney involvement. New numbness, tingling, or weakness in the hands or feet can indicate nerve damage from inflamed vessels. Skin lesions that turn black or develop open sores suggest tissue death from severely compromised blood flow.
Small vessel vasculitis that is diagnosed early and treated aggressively has far better outcomes than disease that is caught late. The difference between the high and low ends of those survival ranges often comes down to how much organ damage occurred before treatment started.